多黏菌素相关性急性肾损伤患者的药代动力学/毒代动力学分析。
Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.
机构信息
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, SUNY, Buffalo, New York, USA.
出版信息
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01367-17. Print 2017 Nov.
Abstract
Acute kidney injury (AKI) occurs in a substantial proportion of critically ill patients receiving intravenous colistin. In the pharmacokinetic/toxicodynamic analysis reported here, the relationship of the occurrence of AKI to exposure to colistin and a number of potential patient factors was explored in 153 critically ill patients, none of whom were receiving renal replacement therapy. Tree-based modeling revealed that the rates of AKI were substantially higher when the average steady-state plasma colistin concentration was greater than ∼2 mg/liter.
摘要
急性肾损伤（AKI）在接受静脉注射黏菌素的危重症患者中占相当大的比例。在本报告的药代动力学/药效动力学分析中，在 153 例危重症患者中探讨了 AKI 的发生与黏菌素暴露以及许多潜在患者因素的关系，这些患者均未接受肾脏替代治疗。基于树的建模显示，当平均稳态血浆黏菌素浓度大于约 2mg/L 时，AKI 的发生率显著升高。
相似文献
1
Pharmacokinetic/Toxicodynamic Analysis of Colistin-Associated Acute Kidney Injury in Critically Ill Patients.多黏菌素相关性急性肾损伤患者的药代动力学/毒代动力学分析。
Antimicrob Agents Chemother. 2017 Oct 24;61(11). doi: 10.1128/AAC.01367-17. Print 2017 Nov.
2
Colistin-associated Acute Kidney Injury in Severely Ill Patients: A Step Toward a Better Renal Care? A Prospective Cohort Study.严重疾病患者中多黏菌素相关性急性肾损伤：迈向更好肾脏护理的一步？一项前瞻性队列研究。
Clin Infect Dis. 2015 Dec 15;61(12):1771-7. doi: 10.1093/cid/civ717. Epub 2015 Sep 9.
3
Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.在重症患者中应用9MU多粘菌素甲磺酸盐负荷剂量后的多粘菌素群体药代动力学。
Antimicrob Agents Chemother. 2015 Dec;59(12):7240-8. doi: 10.1128/AAC.00554-15. Epub 2015 Sep 14.
4
Dosing guidance for intravenous colistin in critically-ill patients.危重症患者静脉注射黏菌素的剂量指南。
Clin Infect Dis. 2017 Mar 1;64(5):565-571. doi: 10.1093/cid/ciw839. Epub 2016 Dec 23.
5
Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.在接受长时间间断肾脏替代治疗的伴有急性肾损伤的危重症患者中，多粘菌素的单剂和多剂药代动力学和总清除率。
J Antimicrob Chemother. 2019 Apr 1;74(4):997-1002. doi: 10.1093/jac/dky511.
6
Steady-state pharmacokinetic and pharmacodynamic profiling of colistin in critically ill patients with multi-drug-resistant gram-negative bacterial infections, along with differences in clinical, microbiological and safety outcome.多药耐药革兰氏阴性菌感染危重症患者中黏菌素的稳态药代动力学和药效学特征，以及临床、微生物学和安全性结局的差异。
Basic Clin Pharmacol Toxicol. 2021 Jan;128(1):128-140. doi: 10.1111/bcpt.13482. Epub 2020 Sep 4.
7
Acute kidney injury during colistin therapy: a prospective study in patients with extensively-drug resistant Acinetobacter baumannii infections.多黏菌素治疗期间的急性肾损伤：广泛耐药鲍曼不动杆菌感染患者的前瞻性研究。
Clin Microbiol Infect. 2016 Dec;22(12):984-989. doi: 10.1016/j.cmi.2016.08.004. Epub 2016 Aug 18.
8
Higher incidence of acute kidney injury with intravenous colistimethate sodium compared with polymyxin B in critically ill patients at a tertiary care medical center.与多黏菌素 B 相比，在三级医疗中心的危重症患者中，静脉注射黏菌素甲磺酸钠的急性肾损伤发生率更高。
Clin Infect Dis. 2013 Nov;57(9):1300-3. doi: 10.1093/cid/cit453. Epub 2013 Jul 9.
9
Colistin nephrotoxicity in critically ill patients after implementation of a new dosing strategy.实施新给药策略后重症患者的黏菌素肾毒性
J Infect Dev Ctries. 2019 Oct 31;13(10):877-885. doi: 10.3855/jidc.11413.
10
Acute kidney injury following colistin treatment in critically-ill patients: may glucocorticoids protect?重症患者使用黏菌素治疗后发生急性肾损伤：糖皮质激素可起保护作用吗？
J Chemother. 2021 Apr;33(2):85-94. doi: 10.1080/1120009X.2020.1770027. Epub 2020 Jun 5.
引用本文的文献
1
The pharmacokinetic-nephrotoxicity relationships of CMS and CMS-E2 from the perspective of plasma and kidney drug concentrations in rats.从大鼠血浆和肾脏药物浓度的角度探讨CMS和CMS-E2的药代动力学-肾毒性关系。
Sci Rep. 2025 May 10;15(1):16299. doi: 10.1038/s41598-025-96407-7.
2
Amphiphilic mPEG-PLGA copolymer nanoparticles co-delivering colistin and niclosamide to treat colistin-resistant Gram-negative bacteria infections.两亲性甲氧基聚乙二醇-聚乳酸-羟基乙酸共聚物纳米颗粒共递送黏菌素和氯硝柳胺以治疗耐黏菌素革兰氏阴性菌感染。
Commun Biol. 2025 Apr 29;8(1):673. doi: 10.1038/s42003-025-08095-8.
3
A Systematic Review of Pharmacokinetic Studies of Colistin and Polymyxin B in Adult Populations.成人人群中黏菌素和多黏菌素B药代动力学研究的系统评价
Clin Pharmacokinet. 2025 May;64(5):655-689. doi: 10.1007/s40262-025-01488-2. Epub 2025 Apr 17.
4
High-dose colistin pharmacokinetics in critically ill patients receiving continuous renal replacement therapy.接受连续性肾脏替代治疗的重症患者的大剂量黏菌素药代动力学
Ann Intensive Care. 2024 Sep 28;14(1):152. doi: 10.1186/s13613-024-01384-1.
5
Modification of the Antibiotic, Colistin, with Dextrin Causes Enhanced Cytotoxicity and Triggers Apoptosis in Myeloid Leukemia.用糊精修饰抗生素多粘菌素会增强细胞毒性并引发髓系白血病细胞凋亡。
Int J Nanomedicine. 2024 Jun 7;19:5419-5437. doi: 10.2147/IJN.S449185. eCollection 2024.
6
Genetic predisposition and high exposure to colistin in the early treatment period as independent risk factors for colistin-induced nephrotoxicity.遗传易感性和早期治疗期间高暴露于黏菌素是黏菌素诱导的肾毒性的独立危险因素。
Clin Transl Sci. 2024 Mar;17(3):e13764. doi: 10.1111/cts.13764.
7
Synergistic Activity of Colistin in Combination with Clofoctol against Colistin Resistant Gram-Negative Pathogens.黏菌素与氯氟醇联合对耐黏菌素革兰氏阴性病原菌的协同活性
Microbiol Spectr. 2023 Feb 21;11(2):e0427522. doi: 10.1128/spectrum.04275-22.
8
Incidence and Risk Factors of Colistin-Induced Nephrotoxicity Associated with The International Consensus Guidelines for the Optimal Use of the Polymyxins: A Retrospective Study in a Tertiary Care Hospital, Saudi Arabia.与多粘菌素最佳使用国际共识指南相关的黏菌素诱导肾毒性的发生率及危险因素：沙特阿拉伯一家三级护理医院的回顾性研究
Antibiotics (Basel). 2022 Nov 7;11(11):1569. doi: 10.3390/antibiotics11111569.
9
Pharmacokinetic Characteristics of Nebulized Colistimethate Sodium Using Two Different Types of Nebulizers in Critically Ill Patients with Ventilator-Associated Respiratory Infections.在患有呼吸机相关性呼吸道感染的重症患者中使用两种不同类型雾化器雾化多粘菌素甲磺酸钠的药代动力学特征
Antibiotics (Basel). 2022 Nov 1;11(11):1528. doi: 10.3390/antibiotics11111528.
10
Therapeutic Options and Outcomes for the Treatment of Neonates and Preterms with Gram-Negative Multidrug-Resistant Bacteria: A Systematic Review.革兰氏阴性多重耐药菌感染的新生儿和早产儿治疗选择及结果：一项系统评价
Antibiotics (Basel). 2022 Aug 10;11(8):1088. doi: 10.3390/antibiotics11081088.
本文引用的文献
1
Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate.验证黏菌素甲磺酸盐治疗患者时的血药浓度界值作为预测肾毒性的指标。
Int J Antimicrob Agents. 2016 Dec;48(6):725-727. doi: 10.1016/j.ijantimicag.2016.08.020. Epub 2016 Oct 7.
2
Dosing guidance for intravenous colistin in critically-ill patients.危重症患者静脉注射黏菌素的剂量指南。
Clin Infect Dis. 2017 Mar 1;64(5):565-571. doi: 10.1093/cid/ciw839. Epub 2016 Dec 23.
3
Nephrotoxicity of Polymyxins: Is There Any Difference between Colistimethate and Polymyxin B?多粘菌素的肾毒性：粘菌素甲磺酸钠与多粘菌素B之间有差异吗？
Antimicrob Agents Chemother. 2017 Feb 23;61(3). doi: 10.1128/AAC.02319-16. Print 2017 Mar.
4
Updated US and European Dose Recommendations for Intravenous Colistin: How Do They Perform?美国和欧洲更新的静脉注射多粘菌素剂量建议：它们的效果如何？
Clin Infect Dis. 2016 Mar 1;62(5):552-558. doi: 10.1093/cid/civ964. Epub 2015 Nov 25.
5
The safety of polymyxin antibiotics.多粘菌素类抗生素的安全性。
Expert Opin Drug Saf. 2015;14(11):1687-701. doi: 10.1517/14740338.2015.1088520. Epub 2015 Sep 12.
6
New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection.在小鼠大腿和肺部感染模型中，对全身性给予多粘菌素治疗铜绿假单胞菌和鲍曼不动杆菌的新的药代动力学/药效学研究：肺部感染中的反应较小。
J Antimicrob Chemother. 2015 Dec;70(12):3291-7. doi: 10.1093/jac/dkv267. Epub 2015 Aug 27.
7
Strategies for the safe use of colistin.黏菌素安全使用策略。
Expert Rev Anti Infect Ther. 2015;13(10):1237-47. doi: 10.1586/14787210.2015.1070097. Epub 2015 Jul 16.
8
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus.多黏菌素 B 和黏菌素临床使用优化框架：普拉托共识。
Lancet Infect Dis. 2015 Feb;15(2):225-34. doi: 10.1016/S1473-3099(14)70850-3. Epub 2014 Oct 21.
9
In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.黏菌素甲磺酸钠与多黏菌素B治疗相关的比较性肾毒性率的体外评估及多中心队列研究
Antimicrob Agents Chemother. 2014 May;58(5):2740-6. doi: 10.1128/AAC.02476-13. Epub 2014 Feb 24.
10
Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.多黏菌素 B 或黏菌素甲磺酸钠治疗患者发生急性肾损伤的危险因素。
Int J Antimicrob Agents. 2014 Apr;43(4):349-52. doi: 10.1016/j.ijantimicag.2013.12.002. Epub 2013 Dec 15.
Zotero 插件